- Home
- QSI vs LRMR Comparison
QSI vs LRMR Comparison
Compare QSI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | LRMR |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 280.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | QSI | LRMR |
|---|---|---|
| Price | $0.93 | $5.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.00 | ★ $16.29 |
| AVG Volume (30 Days) | 3.0M | ★ 6.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $196.35 | N/A |
| Revenue Next Year | $229.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $1.61 |
| 52 Week High | $3.10 | $6.42 |
Technical Indicators
Market Signals| Indicator | QSI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 68.17 |
| Support Level | N/A | $3.18 |
| Resistance Level | $1.03 | $6.42 |
| Average True Range (ATR) | 0.06 | 0.53 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 42.13 | 77.46 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.